A. Altdorfer

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

R. Greil, Y. Yazdanpanah, C. Marquette, 2021, The Lancet Infectious Diseases.

Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit—A Monocentric Retrospective Observational Study

E. Gregoire, G. Darcis, F. Moerman, 2021, Pathogens.

A rare case of invasive pulmonary aspergillosis presenting as organizing pneumonia due to Aspergillus niger in an immunocompetent host

J. Maertens, F. Moerman, Raphaël Schils, 2021, Respiratory medicine case reports.

A rare case of voluminous brain abscess due to Actinomyces meyeri and Aggregatibacter aphrophilus: is there any evidence for a prolonged antibiotic oral relay?

P. Mathonet, F. Moerman, A. Altdorfer, 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Mycobacterium avium complex and Cryptococcus neoformans co-infection in a patient with acquired immunodeficiency syndrome: a case report

E. Gregoire, G. Darcis, F. Moerman, 2021, Acta Clinica Belgica.

Aggregatibacter aphrophilus spinal epidural abscess

F. Moerman, A. Altdorfer, P. Gavage, 2020, BMJ Case Reports.

Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial

R. Greil, Y. Yazdanpanah, D. Costagliola, 2021, SSRN Electronic Journal.

Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial

R. Greil, Y. Yazdanpanah, F. Raffi, 2022, medRxiv.